Pipeline

MBF-118

MBF-118 is a potent and selective, covalent, partial agonist of the PPARγ nuclear receptor as a potential therapy for fibrostenosing Crohn’s disease (FSCD) 

 MBF-118 has completed a phase IIa PoC trial in FSCD

                           

MBF-362

MBF-362 is an antagonist of the prostaglandin EP4 receptor as a novel non-hormonal therapy for endometriosis

MBF-362 also completed a phase Ib trial for solid tumours

MBF-015

MBF-015 is a novel and selective HDAC1/2 inhibitor as a potential disease modifying therapy for synaptic loss in neurodegenerative diseases

MBF-015 has completed a phase IIa PoC trial in Huntington’s disease